VJHemOnc is committed to improving our service to you

ICML 2019 | DIAL me in: dual immunodulation in aggressive lymphoma

VJHemOnc is committed to improving our service to you

Jose Villasboas

Jose Villasboas, MD, Mayo Clinic, Rochester, Minnesota, MN, discusses the rationale and design of the ongoing Phase II Dual Immunomodulation in Aggressive Lymphoma (DIAL) trial (NCT03038672). This trial investigates varilumab plus nivolumab in aggressive B-cell lymphomas. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter